BioPharm International, April 2022 Issue

Expanding Viral Vector Manufacturing

April 01, 2022

Outsourcing

35

4

BioPharm International spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors.

Technology and CAPA

April 01, 2022

Quality/Regulations

35

4

Performing corrective action and preventive action (CAPA) activities is often necessary to investigate a manufacturing deviation and prevent it from reoccurring. BioPharm International asked Joe O’Gorman, head of Global Operations at LZ Lifescience, a Cognizant Company, about the role technology plays in performing CAPAs.

FDA Maps Strategies to Advance Pharmaceutical Quality

April 01, 2022

Regulatory Beat

35

4

Quality metrics and more domestic production aim to avoid supply disruptions and drug shortages.

Next Level Interrogation

April 01, 2022

From the Editor

35

4

3D cell cultures could provide key avenues to unlocking critical information.

Verifying Compendial Methods

April 01, 2022

Ask The Expert

35

4

Experts Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, and Steven J. Lynn, executive vice-president, Pharmaceuticals for Regulatory Compliance Associates, discuss the verification of compendial methods.

Major League Moves

April 01, 2022

From the CEO

35

4

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.